Emerging therapies in sight for the fight against dedifferentiated thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 2, 2011, Pages 347-350

  Benvenga, Salvatore ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; AXITINIB; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; MOTESANIB; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLO[3,4 D]PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; SEMAXANIB; SORAFENIB; SUNITINIB; THYROTROPIN; VANDETANIB; VASCULOTROPIN RECEPTOR;

CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CARDIOVASCULAR DISEASE; DEDIFFERENTIATED THYROID CANCER; EDITORIAL; GASTROINTESTINAL DISEASE; GENE MUTATION; GENE OVEREXPRESSION; HEMATOLOGIC DISEASE; HUMAN; LIVER DISEASE; NEUROMUSCULAR DISEASE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN DISEASE; SURVIVAL RATE; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CLINICAL TRIALS, PHASE II AS TOPIC; ENZYME INHIBITORS; GENE THERAPY; HUMANS; PROTEIN-TYROSINE KINASES; RNA, SMALL INTERFERING; THYROID NEOPLASMS;

EID: 79951690734     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-2799     Document Type: Editorial

References (20)

1. Sarlis NJ, Benvenga S 2004 Molecular signaling in thyroid cancer. In: Farid NR, ed. Molecular basis of thyroid cancer. Boston: Kluwer; 236-263
2. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214
3. Wartofsky L 2009 Highlights of the American Thyroid Association guidelines for management of thyroid nodules and differentiated thyroid carcinoma: the 2009 revision. Thyroid 19:1139-1143
4. Baudin E, Schlumberger M 2007 New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 8:148-156 (Pubitemid 46158381)
5. Krause DS, Van Etten RA 2005 Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172-187 (Pubitemid 41058349)
6. Antonelli A, Ferri C, Ferrari SM, Sebastiani M, Colaci M, Ruffilli I, Fallahi P 6 June 2010 New targeted molecular therapies for dedifferentiated thyroid cancer. J Oncol 10.1155/2010/921682
7. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719
8. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely Jr PE, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684
9. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, Weijers K, Pereira AM, Huijberts M, Kapiteijn E, Romijn JA, Smit JW 2009 Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 161:923-931
10. Leboulleux S, Bastholt L, Krause TM, de La Fouchardiere C, Tennval J, Awada A, Gomez JM, Bonichon F, Spano JP, Tisseron- Carrasco A, Licout M, Schlumberger M, Vandetanib in locally advanced or metastatic differentiated thyroid cancer (papillary or follicular; DTC): a randomized, double-blind phase II trial. Proc 14th International Thyroid Congress, Paris, 2010 (Abstract OC-023)
11. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris 3rd JC, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C, Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center, Mayo Phase 2 Consortium 2010 Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 11:962-972
12. Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Fioravanti A, Sartini S, Minuto M, Piaggi S, Corti A, Alì G, Berti P, Fontanini G, Danesi R, Da Settimo F, Miccoli P 2011 Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab 96:E288-E296
13. Ringe lMD 2008 "Thyroid cancer" cell line misidentification: a time for proactive change. J Clin Endocrinol Metab 93:4226-4227
14. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR 2008 Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93:4331-4341 (Pubitemid 352789529)
15. Pilli T, Prasad KV, Jayarama S, Pacini F, Prabhakar BS 2009 Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. Thyroid 19:1333-1342
16. Blumenthal RD, Goldenberg DM 2007 Methods and goals for the use of in vitro and in vivo chemosensitivity testing. Mol Biotechnol 35:185-197 (Pubitemid 46631888)
17. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Marchetti I, Ugolini C, Basolo F, Miccoli P, Ferrannini E 2008 Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. Eur J Endocrinol 159:283-291
18. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Barani L, Marchetti I, Ferrannini E, Miccoli P 2008 Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. Clin Endocrinol (Oxf) 69:148-152 (Pubitemid 351847276)
19. Gilbert-Sirieix M, Ripoche H, Malvy C, Massaad-Massade L 2010 Effects of silencing RET/PTC1 junction oncogene in human papillary thyroid carcinoma cells. Thyroid 20:1053-1065
20. Jhiang SM, Shah MH 2010 Prospects for small interfering RNA therapeutics in thyroid cancer. Thyroid 20:1049-1050